SCHEMBL5370557

SCHEMBL5370557

COc1ccc2nc([S+]([O-])Cc3ncc(C)c(OC)c3C)[nH]c2c1S(=O)(=O)c1c(C)cc(OCC(=O)O)cc1C.[Na]

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.40
ATP1A1 P05023 5/20 0.37
ATP1B1 P05026 5/20 0.37
ATP1A3 P13637 5/20 0.37
ATP1B2 P14415 5/20 0.37
ATP4A P20648 5/20 0.37
ATP1A2 P50993 5/20 0.37
ATP4B P51164 5/20 0.37
ATP1B3 P54709 5/20 0.37
FXYD2 P54710 5/20 0.37
ATP1A4 Q13733 5/20 0.37
KMT2A Q03164 4/20 0.37
WDR5 P61964 3/20 0.37
BRS3 P32247 2/20 0.37
KDM4E B2RXH2 1/20 0.37
DDAH1 O94760 1/20 0.37
ABCB11 O95342 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CYP1A2 P05177 1/20 0.37
CHRM2 P08172 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5368139 0.99 CYP2C9 (0.41) CYP2C9ATP1A1ATP1B1ATP1A3ATP1B2
SCHEMBL5763051 0.92 CYP2C9 (0.41) CYP2C9ATP1A1ATP1B1ATP1A3ATP1B2
SCHEMBL6503400 0.88 CYP2C9 (0.39) CYP2C9ATP1A1ATP1B1ATP1A3ATP1B2
SCHEMBL5368127 0.88 CYP2C9 (0.39) CYP2C9ATP1A1ATP1B1ATP1A3ATP1B2
SCHEMBL5369395 0.86 CYP2C9 (0.35) CYP2C9ATP1A1ATP1B1ATP1A3ATP1B2
SCHEMBL5368644 0.86 CYP2C9 (0.41) CYP2C9ATP1A1ATP1B1ATP1A3ATP1B2
SCHEMBL5364408 0.84 CYP2C9 (0.39) CYP2C9ATP1A1ATP1B1ATP1A3ATP1B2
SCHEMBL5370615 0.84 CYP2C9 (0.37) CYP2C9ATP1A1ATP1B1ATP1A3ATP1B2
SCHEMBL5363684 0.83 BRS3 (0.54) CYP2C9ATP1A1ATP1B1ATP1A3ATP1B2
SCHEMBL5368304 0.83 CYP2C9 (0.36) CYP2C9ATP1A1ATP1B1ATP1A3ATP1B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7294716-B2 Process for preparing isomerically pure prodrugs of proton pump inhibitors ALLERGAN, INC. (US) 2007-11-13 US disclosed
EP-1556371-B1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PRODRUGS OF PROTON PUMP INHIBITOR WINSTON PHARMACEUTICALS LLC (US) 2006-04-19 EP disclosed
US-20050182101-A1 Prodrugs of proton pump inhibitors GARST MICHAEL (US) 2005-08-18 US disclosed
US-20050143423-A1 Prodrugs of proton pump inhibitors background of the invention GARST MICHAEL (US) 2005-06-30 US disclosed
US-6897227-B2 Prodrugs of proton pump inhibitors Winston Pharmaceuticals, Inc. (US) 2005-05-24 US disclosed
US-20050038076-A1 Process for preparing isomerically pure prodrugs of proton pump inhibitors ALEVIUM PHARMACEUTICALS, INC. 2005-02-17 US disclosed
US-20040102484-A1 Prodrugs of proton pump inhibitors ALEVIUM PHARMACEUTICALS, INC. 2004-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102484-A1 Prodrugs of proton pump inhibitors ABCB11, SLC10A2, SI CYP2C9 92/4885ATP1A1 22/4885ATP1B1 44/4885
US-20050038076-A1 Process for preparing isomerically pure prodrugs of proton pump inhibitors SI, ATP6AP1, HRH2 CYP2C9 59/4885ATP1A1 168/4885ATP1B1 167/4885
US-20050143423-A1 Prodrugs of proton pump inhibitors background of the invention ABCB11, SLC10A2, SI CYP2C9 49/4885ATP1A1 42/4885ATP1B1 76/4885
US-20050182101-A1 Prodrugs of proton pump inhibitors ABCB11, SLC10A2, SI CYP2C9 83/4885ATP1A1 33/4885ATP1B1 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.